MeiraGTx Holdings plc Ordinary Shares (MGTX)

About MGTX

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

393

Website

meiragtx.com/

Fundamentals

1-day range

$13.65$14.09

Market cap

$1.10B

P/E (trailing)

15.54

P/E (forward)

-9.94

EPS (trailing)

$-1.49

Dividend yield

—

Beta

1.33

Avg. volume

838.0K

Forecasts

7 analyst ratings

MeiraGTx Holdings plc Ordinary Shares Competitors

Chosen by industry and closest market cap.

• MGTX

  MeiraGTx Holdings plc Ordinary Shares

  $13.8

  ▼ 2.40%
  Market cap $1.10BP/E 15.54
  $6.62$15.35
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.16BP/E —
  $6.5$49.95
• IMTX

  Immatics N.V. Ordinary Shares

  $9.45

  ▲ 0.91%
  Market cap $1.21BP/E —
  $5.05$12.41
• INBX

  Inhibrx Biosciences Inc. Common Stock

  $123.93

  ▼ 0.00%
  Market cap $1.21BP/E —
  $26.19$155.29
• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.30BP/E —
  $4.6$25.77
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $884.97MP/E —
  $2.61$6.55
• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $789.57MP/E —
  $3.79$11.45

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $27
  benzinga · 8/14/2026